Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623182 | PMC |
| http://dx.doi.org/10.5114/aoms/193392 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2/MORF4L2/H4K12Ac/CSF1 axis in triple-negative breast cancer.
Biomark Res
January 2025
Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: Although immunotherapy has achieved great progress in advanced triple-negative breast cancer (TNBC), there are still numerous patients who do not benefit from immunotherapy. Therefore, identification of the key molecule that induces immune escape and clarification of its specific mechanism in TNBC are urgently needed.
Methods: In this research, single cell sequencing and bulk sequencing were conducted for biomarker screening.
α7-Nicotinic Acetylcholine Receptor Activation Modulates BV2 Microglial Plasticity via miR-21/TNF-α/NFκB in Oxygen-Glucose Deprivation/Reoxygenation.
J Mol Neurosci
December 2024
Centre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala Lumpur, Malaysia.
Elevated inflammatory reactions are a significant component in cerebral ischemia-reperfusion injury (CIRI). Activation of α7-Nicotinic Acetylcholine Receptor (α7nAChR) reduces stroke-induced inflammation in rats, but the anti-inflammatory pathway in microglia under CIRI condition remains unclear. This study employed qRT-PCR, protein assays, NanoString analysis, and bioinformatics to examine the effects of PNU282987 treatment (α7nAChR agonist) on BV2 microglial functional differentiation in oxygen-glucose deprivation/reoxygenation (OGDR) condition.
View Article and Find Full Text PDFCSF1 mediating 3-hydroxyhexanoate in endometrial cancer: a Mendelian randomization study.
Arch Med Sci
October 2024
Department of Obstetrics and Gynecology, Putuo District Central Hospital, Shanghai Putuo Hospital, Shanghai University of Traditional Chinese Medicine, China.
Mesenchymal stem cells treated with Interleukin-1 beta for mediation of an inflammatory response in human tissues.
Cell Mol Biol (Noisy-le-grand)
November 2024
Stem Cells and Regenerative Medicine, Cell Therapy and Cancer Research (CTCR), King Abdullah International Medical Research Center (KAIMRC), King Abdulaziz Medical City P.O. Box 22490, Riyadh 11426, Saudi Arabia.
Article Synopsis
- The study investigated how different concentrations of interleukin 1 beta (IL-1β) affect the behavior of human bone marrow mesenchymal stem cells (hBM-MSCs) in terms of adhesion, proliferation, and migration.
- Results showed that low concentrations of IL-1β (up to 50 ng/ml) enhanced cell growth and movement, while higher concentrations (100 ng/ml) significantly reduced these activities.
- The study highlights that IL-1β stimulation increases the expression of essential genes related to MSC function, potentially improving their ability to respond to injury in inflamed environments.
Selective Pyk2 inhibition enhances bone restoration through SCARA5-mediated bone marrow remodeling in ovariectomized mice.
Cell Commun Signal
November 2024
Department of Oral Pathobiological Science, Microbiology, Graduate School of Dental Medicine, Hokkaido University, Kita13 Nishi7, Kita-Ku, Sapporo, 060-8586, Japan.
Understanding the intricate cellular interactions involved in bone restoration is crucial for developing effective strategies to promote bone healing and mitigate conditions such as osteoporosis and fractures. Here, we provide compelling evidence supporting the anabolic effects of a pharmacological Pyk2 inhibitor (Pyk2-Inh) in promoting bone restoration. In vitro, Pyk2 signaling inhibition markedly enhances alkaline phosphatase (ALP) activity, a hallmark of osteoblast differentiation, through activation of canonical Wnt/β-catenin signaling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!